A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

The presence of activating epidermal growth factor receptor (EGFR) mutations in patients with lung cancer correlates to improved response to EGFR-tyrosine kinase inhibitors. Here, the authors present a fluorescence-activated cell sorting assay to identify EGFR mutations with functional activity in p...

Full description

Bibliographic Details
Main Authors: Hui Deng, Qian Lei, Chengdi Wang, Zhoufeng Wang, Hai Chen, Gang Wang, Na Yang, Dan Huang, Quanwei Yu, Mengling Yao, Xue Xiao, Guonian Zhu, Cheng Cheng, Yangqian Li, Feng Li, Panwen Tian, Weimin Li
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34627-5

Internet

https://doi.org/10.1038/s41467-022-34627-5

Similar Items